For ADC programs, CRO selection should start with one test: can the partner deliver coordinated, three-analyte hybrid LC-MS/MS data that supports clear PK and safety interpretation?
ADC bioanalysis requires more than a total antibody assay. A technically suitable CRO should quantify three core PK analytes — total antibody, conjugated payload, and free payload — within a coordinated hybrid LC-MS/MS framework. Crystal Bio Solutions applies an adaptable LC-MS/MS approach that measures total antibody by IgG subclass (IgG1: 25–5000 ng/mL; IgG4: 50–5000 ng/mL), conjugated payload (50–5000 ng/mL), and free payload (10–2000 ng/mL), each with linearity of r > 0.999. Without all three measurements, conjugate stability, payload release, and systemic payload exposure may remain insufficiently characterized.
This is why ADC bioanalysis is difficult to outsource well. An antibody-drug conjugate enters circulation as one molecule but behaves as several. The intact conjugate can shed payload through enzymatic or chemical deconjugation, creating species with different drug-to-antibody ratios, deconjugated antibody, and released small-molecule payload. Each species answers a different PK or safety question; no single measurement captures the full profile.
Total antibody shows antibody backbone exposure and supports interpretation of anti-drug antibody effects. Conjugated payload shows payload that remains antibody-associated and available for target-mediated delivery. Free payload shows released small-molecule exposure, which may contribute to off-target or dose-limiting toxicity depending on payload potency, linker stability, exposure, tissue distribution, and study context. Industry working groups and regulators increasingly expect a multi-analyte strategy because a single readout can obscure the in vivo behavior that determines program risk [2,3].
A practical vendor assessment should focus on capabilities, not brand claims. Key requirements include:
Three-analyte coverage in one coordinated framework. Splitting total antibody, conjugated payload, and free payload across vendors can introduce cross-method variability that complicates PK interpretation. A coordinated platform supports more internally consistent data.
Subclass-specific total antibody methods. IgG1 and IgG4 backbones may require different surrogate peptides and capture chemistry. Ask whether the total antibody method is validated or qualified for the construct's subclass rather than adapted from a generic kit.
Sensitivity across the full PK curve. Free payload often circulates at far lower concentrations than antibody, and the tail of the PK curve is where deconjugation and clearance become most informative. The method must capture more than peak exposure.
Hybrid immunocapture–LC-MS/MS design. Immunocapture provides matrix selectivity; LC-MS/MS provides specificity and dynamic range. Together, they create the robustness expected for ADC bioanalysis.
Adaptable, platform-based methods. A transferable framework, with molecule-specific optimization where needed, can shorten method-development timelines in early ADC programs.
A capable partner should also characterize drug-to-antibody ratio (DAR) distribution and conjugate stability over time, because these results help interpret conjugated-payload data. Crystal Bio Solutions performs direct LC-MS analysis of enriched intact ADCs alongside the three-analyte PK panel. The table below summarizes the core requirements.
|
ADC PK analyte |
What it tells you |
Recommended method |
Working range (r > 0.999) |
Why it matters |
|
Total antibody |
Total antibody exposure regardless of drug load; the basis for ADA-corrected PK |
Immunocapture (anti-human IgG) + surrogate-peptide LC-MS/MS, subclass-specific |
IgG1: 25–5000 ng/mL; IgG4: 50–5000 ng/mL |
Used alone, it hides conjugation state and payload release |
|
Conjugated payload |
Payload that remains antibody-associated; reflects conjugate integrity and in vivo deconjugation |
Enzymatic (papain) digestion + precipitation + LC-MS/MS |
50–5000 ng/mL |
A closer readout of antibody-associated payload exposure than total antibody alone |
|
Free payload |
Released cytotoxic small molecule in systemic circulation |
PPT / LLE / SPE extraction + LC-MS/MS |
10–2000 ng/mL |
Assesses systemic payload exposure and potential off-target or dose-limiting toxicity risk |
In practice, a coordinated three-analyte platform should provide clear, comparable data for each PK component. Crystal Bio Solutions has developed an LC-MS/MS-based ADC PK solution on SCIEX 7500+ instrumentation, with fit-for-purpose workflows that can be qualified or validated based on study phase, matrix, species, and regulatory requirements [1,4].
For total antibody, the method captures antibody from the matrix using anti-human IgG immunocapture, then applies denaturation, reduction, alkylation, and enzymatic digestion to release a surrogate peptide for LC-MS/MS quantification. The method is established separately for IgG1 and IgG4 subclasses — IgG1 across 25–5000 ng/mL and IgG4 across 50–5000 ng/mL — rather than assuming one calibration transfers to both.
For conjugated payload, papain digestion followed by precipitation and dilution isolates payload that remains antibody-bound, with a working range of 50–5000 ng/mL. This measurement helps characterize in vivo deconjugation and conjugate stability over time.
For free payload, the released small molecule is recovered by protein precipitation, liquid-liquid extraction, or solid-phase extraction, depending on payload chemistry, and quantified by LC-MS/MS across 10–2000 ng/mL. Each method achieves linearity of r > 0.999.
The business value is speed with consistency. Platform-based workflows help sponsors move from contract initiation to qualified or validated data within early-development timelines, while GLP-compliant laboratories and appropriate quality systems support regulated-study needs when applicable.
Crystal Bio Solutions supports ADC programs with a coordinated, three-analyte hybrid LC-MS/MS framework that quantifies total antibody by IgG1 and IgG4 subclass, conjugated payload, and free payload on SCIEX 7500+ instrumentation. The platform achieves r > 0.999 linearity across the ranges above and characterizes DAR distribution by direct LC-MS analysis of intact ADCs. Work is performed in GLP-compliant laboratories when applicable and supported by appropriate quality systems. By adapting across ADC scaffolds with molecule-specific optimization, the framework can help shorten method-development timelines while delivering internally consistent PK data across all three analytes.
To discuss method design for your ADC program, contact our scientific team for a free consultation.
Look for three-analyte coverage, subclass-appropriate total antibody methods, and sensitivity across the full PK curve — not just peak exposure. The final assay design should reflect the ADC construct, linker-payload chemistry, biological matrix, species, study phase, and applicable regulatory expectations.
Three: total antibody, conjugated payload, and free payload. Total antibody shows antibody backbone exposure. Conjugated payload shows payload that remains antibody-associated and helps characterize deconjugation. Free payload shows released small-molecule exposure that may contribute to systemic safety risk. Together, they describe ADC behavior; alone, each leaves a blind spot.
Total antibody reports how much antibody is present, but not how much drug it still carries. An ADC that has shed most of its payload can show the same total-antibody concentration as a fully conjugated ADC. Without conjugated and free payload data, deconjugation kinetics and payload exposure remain unclear.
1. FDA. Bioanalytical Method Validation Guidance for Industry. U.S. Food and Drug Administration. 2018.
2. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis. 2013;5(9):997–1006. doi:10.4155/bio.13.38
3. Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis. 2013;5(2):201–226. doi:10.4155/bio.12.299
4. ICH. M10 Bioanalytical Method Validation and Study Sample Analysis. International Council for Harmonisation. 2022.